OncoLink Cancer Treatment and Resources
Donate

OncoLink Blogs
espanolespañol
Oncolink Features

Find My Cancer Drug

ABCDEF
GHILMN
OPRSTV


Conferences   /   OncoLink Scientific Meetings Coverage

Gastric MALT Lymphomas Prospective LY03 Randomized Cooperative Trial: Preliminary Results of the Molecular Follow-up



Reviewer: William Levin, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: December 10, 2001

Presenter: F. Bertoni
Presenter's Affiliation: Barts and The London, London
Type of Session: Scientific

Background

  • Gastric MALT lymphoma is most commonly treated with antibiotic therapy directed at H. Pylori infection.
  • Previous studies have shown that eradication of H. pylori can cause complete regression of gastric MALTs.
  • In the current study, investigators wanted to know if the addition of chlorambucil chemotherapy is of benefit after completion of antibiotic therapy.

    Materials and Methods

  • All patients with gastric MALT lymphoma received antibiotic therapy.
  • Following treatment, all pts underwent endoscopy and biopsy.
  • Tissue biopsies were not only reviewed histologically, but also by molecular analysis (polymerase chain reaction).
  • Pts with a histologic CR were randomized to receive either chlorambucil or observation.

    Results

  • 46 of 62 pts (74%) had a histologic CR.
  • Follow-up material was available for molecular analysis in 34 cases.
  • 13 were randomized to chlorambucil, 11 to observation, and 10 had not been randomized.
  • 14 patients failed to achieve a molecular CR.
  • One year after histologic CR, 17 pts were in mCR and 3 achieved mCR by 2 years.
  • At a median follow-up at 2 years, 14(41%) of pts are in mCR.
  • For the pts randomized to chlorambucil, 46%(6/13) achieved mCR, versus 82%(9/11) in the control group.
  • Molecular relapse was seen in 17% of pts in the chlorambucil group and 44% in the observation group.

    Author's Conclusions

  • Less than half of pts with gastric MALT are able to achieve a continuous molecular CR after antibiotic therapy.
  • The addition of chlorambucil to standard therapy does not appear to have a benefit.

    Clinical/Scientific Implications

  • Molecular techniques may offer a more sensitive assessment of post-treatment therapy.
  • More effective therapies are needed in the treatment of gastric MALT lymphoma.

    Oncolink's ASH Coverage made possible by an unrestricted Educational Grant from Amgen.

    • OncoLink I wish u knew...

    Dr. Mao discusses why a patient’s culture plays an important role in treatment decisions. Read more.

    Cancer Types
    Bone Cancer
    Brain Tumors
    Breast Cancer
    Carcinoid Tumors
    Endocrine System Cancers
    Gastrointestinal Cancers
    Gynecologic Cancers
    Head and Neck Cancers
    Leukemia
    Lung Cancers
    Lymphomas
    Myelomas
    Pediatric Cancers
    Penile Cancer
    Prostate Cancer
    Sarcomas
    Skin Cancers
    Testicular Cancer
    Thyroid Cancer
    Urinary Tract Cancers
    OncoLink Vet

    Cancer Treatment
    Biologic Therapy
    Bone Marrow Transplants
    Chemotherapy
    Clinical Trials
    Complementary Medicine
    Gene Therapy
    General Treatment Concerns
    Hormone Therapy
    PDT Center
    Proton Therapy
    Radiation Oncology
    Surgical Oncology
    Targeted Therapies
    Vaccine Therapies

    Cancer Support
    Caregivers
    Hospice Care and Bereavement
    Nutrition and Cancer
    Sexuality & Fertility
    Side Effects
    Support
    Survivorship
    Exercise and Cancer

    Cancer Resources
    Cancer News
    OncoLink University
    Nurses' Notes
    Conferences
    Newly Diagnosed Patients
    Causes and Prevention
    Legal and Financial Information for Patients
    LGBT Resources
    NCI Resources
    Global Resources
    Cancer Resource List
    Resources for Young Adults

    OncoLink Media Library
    OncoLink TV
    Book, Music and Video Reviews


    Ask the Experts
    Brown Bag Chat
    Tracy's Corner

    About OncoLink
    About OncoLink
    Giving to OncoLink
    Contact Information
    Usage Policy
    Editorial Board
    How to Partner with OncoLink
    Link to OncoLink
    Mission Statement

    OncoLink Cancer Resources RSS What's New RSS

    Site Map   |   About OncoLink   |   Privacy statement   |   Disclaimer   |   Link to OncoLink   |   Home
    For assistance please visit our HELP section

    Trustees of the University of Pennsylvania